![Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin - Rejdak - 2023 - Medicinal Research Reviews - Wiley Online Library Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin - Rejdak - 2023 - Medicinal Research Reviews - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4fa3a19b-0c63-4ff1-b463-c2c80b76d8fe/med21960-fig-0002-m.jpg)
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin - Rejdak - 2023 - Medicinal Research Reviews - Wiley Online Library
![Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2015.62.9170/asset/images/jco629170ta3.jpeg)
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology
Fraser | Metavivorship and Narrative Repair in Teva Harrison's In-Between Days (2016) | Graphic Medicine Review
Flashback Foreword: Estrogen Receptor by Immunohistochemistry in Breast Cancer | Journal of Clinical Oncology
![Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2015.62.9170/asset/images/jco629170t1.jpeg)
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology
![Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2015.62.9170/asset/images/jco629170f3.jpeg)
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial | Journal of Clinical Oncology
![Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2023.41.issue-6/asset/1868422c-b518-8422-9b51-68422c9b5186/jco.2023.41.issue-6.cover.gif)